https://www.biocon.com/ 2020-09-11T03:38:56+00:00 1.00 https://www.biocon.com/about-us/ 2020-09-11T03:38:57+00:00 0.80 https://www.biocon.com/about-us/who-we-are/ 2020-09-11T03:38:59+00:00 0.80 https://www.biocon.com/about-us/our-key-priorities/ 2020-09-11T03:39:00+00:00 0.80 https://www.biocon.com/about-us/board-of-directors-biocon/ 2020-09-11T03:39:01+00:00 0.80 https://www.biocon.com/about-us/management-team/ 2020-09-11T03:39:03+00:00 0.80 https://www.biocon.com/about-us/our-legacy/ 2020-09-11T03:39:04+00:00 0.80 https://www.biocon.com/about-us/factsheet-biocon/ 2020-09-11T03:39:06+00:00 0.80 https://www.biocon.com/about-us/our-stories/ 2020-09-11T03:39:07+00:00 0.80 https://www.biocon.com/about-us/biocon-awards-recognition/ 2020-09-11T03:39:09+00:00 0.80 https://www.biocon.com/products/ 2020-09-11T03:39:10+00:00 0.80 https://www.biocon.com/products/key-therapeutic-areas/ 2020-09-11T03:39:12+00:00 0.80 https://www.biocon.com/products/generics/ 2020-09-11T03:39:13+00:00 0.80 https://www.biocon.com/products/biosimilars/ 2020-09-11T03:39:14+00:00 0.80 https://www.biocon.com/products/novel-biologics/ 2020-09-11T03:39:16+00:00 0.80 https://www.biocon.com/products/branded-formulations/ 2020-09-11T03:39:17+00:00 0.80 https://www.biocon.com/businesses/ 2020-09-11T03:39:18+00:00 0.80 https://www.biocon.com/businesses/generics/ 2020-09-11T03:39:20+00:00 0.80 https://www.biocon.com/businesses/generics/api-overview/ 2020-09-11T03:39:21+00:00 0.80 https://www.biocon.com/businesses/generics/generic-formulations/ 2020-09-11T03:39:23+00:00 0.80 https://www.biocon.com/businesses/generics/c-maps/ 2020-09-11T03:39:24+00:00 0.80 https://www.biocon.com/businesses/generics/quality-compliance/ 2020-09-11T03:39:25+00:00 0.80 https://www.biocon.com/businesses/generics/overview-manufacturing-operations/ 2020-09-11T03:39:27+00:00 0.80 https://www.biocon.com/businesses/generics/overview-rnd/ 2020-09-11T03:39:28+00:00 0.80 https://www.biocon.com/businesses/generics/small-molecule-regulatory/ 2020-09-11T03:39:29+00:00 0.80 https://www.biocon.com/businesses/biosimilars/ 2020-09-11T03:39:31+00:00 0.80 https://www.biocon.com/businesses/biosimilars/our-work-in-biosimilars/ 2020-09-11T03:39:32+00:00 0.80 https://www.biocon.com/businesses/biosimilars/global-portfolio/ 2020-09-11T03:39:34+00:00 0.80 https://www.biocon.com/businesses/biosimilars/wide-global-footprint/ 2020-09-11T03:39:35+00:00 0.80 https://www.biocon.com/businesses/biosimilars/quality-and-compliance/ 2020-09-11T03:39:36+00:00 0.80 https://www.biocon.com/businesses/biosimilars/partners/ 2020-09-11T03:39:38+00:00 0.80 https://www.biocon.com/businesses/biosimilars/global-scale-manufacturing/ 2020-09-11T03:39:39+00:00 0.80 https://www.biocon.com/businesses/biosimilars/research-and-development/ 2020-09-11T03:39:40+00:00 0.80 https://www.biocon.com/businesses/biosimilars/branded-formulations/ 2020-09-11T03:39:42+00:00 0.80 https://www.biocon.com/businesses/novel-biologics/ 2020-09-11T03:39:43+00:00 0.80 https://www.biocon.com/businesses/novel-biologics/biocon-and-novels/ 2020-09-11T03:39:45+00:00 0.80 https://www.biocon.com/businesses/novel-biologics/nimotuzumab/ 2020-09-11T03:39:46+00:00 0.80 https://www.biocon.com/businesses/research-and-development/ 2020-09-11T03:39:47+00:00 0.80 https://www.biocon.com/investor-relations/ 2020-09-11T03:39:49+00:00 0.80 https://www.biocon.com/investor-relations/fact-sheet/ 2020-09-11T03:39:50+00:00 0.80 https://www.biocon.com/investor-relations/financial-information/ 2020-09-11T03:39:51+00:00 0.80 https://www.biocon.com/investor-relations/financial-information/annual-reports/ 2020-09-11T03:39:53+00:00 0.80 https://www.biocon.com/investor-relations/financial-information/quarterly-reports/ 2020-09-11T03:39:54+00:00 0.80 https://www.biocon.com/investor-relations/financial-information/key-figures-annual-and-quarterly/ 2020-09-11T03:39:55+00:00 0.80 https://www.biocon.com/investor-relations/financial-information/earning-call-transcripts/ 2020-09-11T03:39:57+00:00 0.80 https://www.biocon.com/investor-relations/financial-information/subsidiary-financials/ 2020-09-11T03:39:58+00:00 0.80 https://www.biocon.com/investor-relations/financial-information/investor-presentations/ 2020-09-11T03:40:00+00:00 0.80 https://www.biocon.com/investor-relations/corporate-governance/ 2020-09-11T03:40:01+00:00 0.80 https://www.biocon.com/investor-relations/corporate-governance/overview/ 2020-09-11T03:40:02+00:00 0.80 https://www.biocon.com/investor-relations/corporate-governance/board-of-directors/ 2020-09-11T03:40:04+00:00 0.80 https://www.biocon.com/investor-relations/corporate-governance/board-committees/ 2020-09-11T03:40:05+00:00 0.80 https://www.biocon.com/investor-relations/corporate-governance/our-leadership/ 2020-09-11T03:40:06+00:00 0.80 https://www.biocon.com/investor-relations/corporate-governance/corporate-structure/ 2020-09-11T03:40:08+00:00 0.80 https://www.biocon.com/investor-relations/corporate-governance/governance-documents-policies/ 2020-09-11T03:40:09+00:00 0.80 https://www.biocon.com/investor-relations/share-information/ 2020-09-11T03:40:11+00:00 0.80 https://www.biocon.com/investor-relations/share-information/share-graph/ 2020-09-11T03:40:12+00:00 0.80 https://www.biocon.com/investor-relations/share-information/share-series/ 2020-09-11T03:40:14+00:00 0.80 https://www.biocon.com/investor-relations/share-information/share-price-look-up/ 2020-09-11T03:40:15+00:00 0.80 https://www.biocon.com/investor-relations/share-information/investment-calculator/ 2020-09-11T03:40:16+00:00 0.80 https://www.biocon.com/investor-relations/share-information/share-price-alerts/ 2020-09-11T03:40:18+00:00 0.80 https://www.biocon.com/investor-relations/share-information/fragulizer/ 2020-09-11T03:40:19+00:00 0.80 https://www.biocon.com/investor-relations/share-information/dividends/ 2020-09-11T03:40:20+00:00 0.80 https://www.biocon.com/investor-relations/share-information/unclaimed-and-unpaid-dividend/ 2020-09-11T03:40:22+00:00 0.80 https://www.biocon.com/investor-relations/share-information/iepf/ 2020-09-11T03:40:23+00:00 0.80 https://www.biocon.com/investor-relations/shareholder-services/ 2020-09-11T03:40:24+00:00 0.80 https://www.biocon.com/investor-relations/shareholder-services/annual-general-meeting/ 2020-09-11T03:40:26+00:00 0.80 https://www.biocon.com/investor-relations/shareholder-services/postal-ballot/ 2020-09-11T03:40:27+00:00 0.80 https://www.biocon.com/investor-relations/shareholder-services/investor-feedback/ 2020-09-11T03:40:28+00:00 0.80 https://www.biocon.com/investor-relations/shareholder-services/investor-faq/ 2020-09-11T03:40:30+00:00 0.80 https://www.biocon.com/investor-relations/financial-calendar/ 2020-09-11T03:40:31+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/ 2020-09-11T03:40:33+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/notice-of-board-meeting/ 2020-09-11T03:40:35+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/investors-meeting/ 2020-09-11T03:40:36+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/press-release/ 2020-09-11T03:40:37+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/shareholding-pattern/ 2020-09-11T03:40:39+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/corporate-governance-report/ 2020-09-11T03:40:40+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/newspaper-advertisement/ 2020-09-11T03:40:41+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/rpt-disclosure/ 2020-09-11T03:40:43+00:00 0.80 https://www.biocon.com/investor-relations/stock-exchange-disclosures/other-announcements-disclosures/ 2020-09-11T03:40:44+00:00 0.80 https://www.biocon.com/investor-relations/analyst-coverage/ 2020-09-11T03:40:45+00:00 0.80 https://www.biocon.com/code-of-conduct/ 2020-09-11T03:40:47+00:00 0.80 https://www.biocon.com/investor-relations/email-subscription-centre/ 2020-09-11T03:40:48+00:00 0.80 https://www.biocon.com/investor-relations/contact-investors-relation/ 2020-09-11T03:40:49+00:00 0.80 https://www.biocon.com/careers/ 2020-09-11T03:40:51+00:00 0.80 https://www.biocon.com/careers/working-with-us/ 2020-09-11T03:40:52+00:00 0.80 https://www.biocon.com/careers/functions/ 2020-09-11T03:40:54+00:00 0.80 https://www.biocon.com/careers/our-culture/ 2020-09-11T03:40:55+00:00 0.80 https://www.biocon.com/careers/diversity-and-inclusion/ 2020-09-11T03:40:56+00:00 0.80 https://www.biocon.com/careers/learning-development/ 2020-09-11T03:40:58+00:00 0.80 https://www.biocon.com/careers/awards-recognition/ 2020-09-11T03:40:59+00:00 0.80 https://www.biocon.com/careers/benefits/ 2020-09-11T03:41:00+00:00 0.80 https://www.biocon.com/careers/meet-our-employees/ 2020-09-11T03:41:02+00:00 0.80 https://www.biocon.com/careers/career-faq/ 2020-09-11T03:41:03+00:00 0.80 https://www.biocon.com/responsibility/ 2020-09-11T03:41:05+00:00 0.80 https://www.biocon.com/responsibility/biocon-foundation/ 2020-09-11T03:41:06+00:00 0.80 https://www.biocon.com/responsibility/biocon-foundation/social-impact/ 2020-09-11T03:41:07+00:00 0.80 https://www.biocon.com/responsibility/biocon-foundation/team-and-partners/ 2020-09-11T03:41:09+00:00 0.80 https://www.biocon.com/responsibility/biocon-foundation/grant-in-aid/ 2020-09-11T03:41:10+00:00 0.80 https://www.biocon.com/responsibility/biocon-foundation/biocon-foundation-awards-and-recognition/ 2020-09-11T03:41:12+00:00 0.80 https://www.biocon.com/responsibility/sustainability/ 2020-09-11T03:41:13+00:00 0.80 https://www.biocon.com/news-biocon/ 2020-09-11T03:41:14+00:00 0.80 https://www.biocon.com/news-biocon/press-releases/ 2020-09-11T03:41:16+00:00 0.80 https://www.biocon.com/news-biocon/company-statements/ 2020-09-11T03:41:17+00:00 0.80 https://www.biocon.com/news-biocon/media-stories/ 2020-09-11T03:41:19+00:00 0.80 https://www.biocon.com/news-biocon/image-gallery-biocon/ 2020-09-11T03:41:22+00:00 0.80 https://www.biocon.com/news-biocon/video-gallery-biocon/ 2020-09-11T03:41:23+00:00 0.80 https://www.biocon.com/news-biocon/events-and-calendar-biocon/ 2020-09-11T03:41:25+00:00 0.80 https://www.biocon.com/news-biocon/media-contact/ 2020-09-11T03:41:26+00:00 0.80 https://www.biocon.com/more/ 2020-09-11T03:41:27+00:00 0.80 https://www.biocon.com/more/contact-us/ 2020-09-11T03:41:29+00:00 0.80 https://www.biocon.com/more/patient-literature/ 2020-09-11T03:41:30+00:00 0.80 https://www.biocon.com/more/biocon-malaysia/ 2020-09-11T03:41:31+00:00 0.80 https://www.biocon.com/businesses/bicara/ 2020-09-11T03:41:33+00:00 0.80 https://www.biocon.com/hope-now-within-reach/ 2020-09-11T03:41:34+00:00 0.80 https://www.biocon.com/biocon-presented-insights-into-clinical-study-that-enabled-dcgi-approval-of-itolizumab-for-covid-19/ 2020-09-11T03:41:35+00:00 0.80 https://www.biocon.com/research-saves-lives/ 2020-09-11T03:41:37+00:00 0.80 https://www.biocon.com/meeting-the-unmet-patient-needs/ 2020-09-11T03:41:38+00:00 0.80 https://www.biocon.com/10-c-answer-to-diabetes/ 2020-09-11T03:41:39+00:00 0.80 https://www.biocon.com/biocon-biologics-and-mylan-announce-launch-of-semglee-insulin-glargine-injection-in-the-u-s-to-expand-access-for-patients-living-with-diabetes/ 2020-09-11T03:41:41+00:00 0.80 https://www.biocon.com/tata-capital-growth-fund-to-invest-usd-30-million-rs-225-crore-in-biocon-biologics-for-an-equity-stake-of-0-85-deal-values-biocon-biologics-at-usd-3-5-billion/ 2020-09-11T03:41:42+00:00 0.80 https://www.biocon.com/biocon-q1fy21-revenue-at-rs-1690-cr-up-14-ebitda-at-rs-432-cr-net-profit-from-continuing-ops-at-rs-153-cr-generics-up-16-at-rs-599-cr-biosimilars-up-19-at-rs-692-cr/ 2020-09-11T03:41:43+00:00 0.80 https://www.biocon.com/sitemap/ 2020-09-11T03:41:47+00:00 0.80 https://www.biocon.com/safe-harbour/ 2020-09-11T03:41:48+00:00 0.80 https://www.biocon.com/privacy-policy-biocon/ 2020-09-11T03:41:50+00:00 0.80 https://www.biocon.com/terms-of-use/ 2020-09-11T03:41:51+00:00 0.80 https://www.biocon.com/about-us/who-we-are/biocons-strengths/ 2020-09-11T03:41:54+00:00 0.64 https://www.biocon.com/about-us/who-we-are/biocons-business-model/ 2020-09-11T03:41:56+00:00 0.64 https://www.biocon.com/about-us/who-we-are/biocon-is-a-differentiated-player/ 2020-09-11T03:41:57+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/kiran-mazumdar-shaw-biocon/ 2020-09-11T03:41:58+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/john-shaw-biocon/ 2020-09-11T03:42:00+00:00 0.64 https://www.biocon.com/about-us/management-team/siddharth-mittal-biocon/ 2020-09-11T03:42:02+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/prof-ravi-mazumdar-biocon/ 2020-09-11T03:42:03+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/mary-harney-biocon/ 2020-09-11T03:42:04+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/vijay-kuchroo-biocon/ 2020-09-11T03:42:06+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/bobby-parikh-biocon/ 2020-09-11T03:42:07+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/m-damodaran-biocon/ 2020-09-11T03:42:08+00:00 0.64 https://www.biocon.com/about-us/board-of-directors-biocon/daniel-bradbury-biocon/ 2020-09-11T03:42:10+00:00 0.64 https://www.biocon.com/about-us/management-team/christiane-hamacher-biocon/ 2020-09-11T03:42:12+00:00 0.64 https://www.biocon.com/about-us/management-team/jonathan-hunt-biocon/ 2020-09-11T03:42:14+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/08/Biocon-Factsheet-w.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/09/Biocon-Biologics-Factsheet-20200901.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Syngene-Factsheet-Aug-14.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/lets-fight-the-covid-19-outbreak/ 2020-09-11T03:42:19+00:00 0.64 https://www.biocon.com/careers/meet-our-employees/abhijit-zutshi-employee-story/ 2020-09-11T03:42:21+00:00 0.64 https://www.biocon.com/careers/meet-our-employees/renuka-ganesh-employee-story/ 2020-09-11T03:42:23+00:00 0.64 https://www.biocon.com/careers/meet-our-employees/bhamidipati-prasad-employee-story/ 2020-09-11T03:42:25+00:00 0.64 https://www.biocon.com/careers/meet-our-employees/ankur-bhatnagar-employee-story/ 2020-09-11T03:42:27+00:00 0.64 https://www.biocon.com/careers/meet-our-employees/grija-kelath-employee-story/ 2020-09-11T03:42:29+00:00 0.64 https://www.biocon.com/patient-stories/patients-stories-insulin-glargine/ 2020-09-11T03:42:32+00:00 0.64 https://www.biocon.com/patient-stories/patient-stories-biosimilar-trastuzumab/ 2020-09-11T03:42:34+00:00 0.64 https://www.biocon.com/patient-stories/patient-stories-bevacizumab/ 2020-09-11T03:42:36+00:00 0.64 https://www.biocon.com/responsibility/elaj-smart-clinics/ 2020-09-11T03:42:37+00:00 0.64 https://www.biocon.com/responsibility/oral-cancer-screening-case-study/ 2020-09-11T03:42:38+00:00 0.64 https://www.biocon.com/responsibility/biocon-academy-bridging-the-gap-between-academia-and-biotech-industry/ 2020-09-11T03:42:40+00:00 0.64 https://www.biocon.com/products/key-therapeutic-areas/diabetes/ 2020-09-11T03:42:41+00:00 0.64 https://www.biocon.com/products/key-therapeutic-areas/cancer/ 2020-09-11T03:42:42+00:00 0.64 https://www.biocon.com/products/key-therapeutic-areas/auto-immune-diseases/ 2020-09-11T03:42:44+00:00 0.64 https://www.biocon.com/patient-stories/ 2020-09-11T03:42:45+00:00 0.64 https://www.biocon.com/products/branded-formulations/metabolics-branded-formulations-2/ 2020-09-11T03:42:47+00:00 0.64 https://www.biocon.com/products/branded-formulations/oncology-branded-formulations/ 2020-09-11T03:42:50+00:00 0.64 https://www.biocon.com/products/branded-formulations/immunotherapy-branded-formulations/ 2020-09-11T03:42:52+00:00 0.64 https://www.biocon.com/products/branded-formulations/nephrology-branded-formulations/ 2020-09-11T03:42:54+00:00 0.64 https://www.biocon.com/products/branded-formulations/ccd/ 2020-09-11T03:42:56+00:00 0.64 https://www.biocon.com/businesses/generics/api-strategy/ 2020-09-11T03:42:57+00:00 0.64 https://www.biocon.com/businesses/generics/api-portfolio/ 2020-09-11T03:42:59+00:00 0.64 https://www.biocon.com/businesses/generics/brand-equity/ 2020-09-11T03:43:00+00:00 0.64 https://www.biocon.com/businesses/generics/strategy-reliability/ 2020-09-11T03:43:01+00:00 0.64 https://www.biocon.com/businesses/generics/strategy-access/ 2020-09-11T03:43:03+00:00 0.64 https://www.biocon.com/businesses/generics/strategy-portfolio/ 2020-09-11T03:43:04+00:00 0.64 https://www.biocon.com/businesses/generics/pipeline/ 2020-09-11T03:43:05+00:00 0.64 https://www.biocon.com/businesses/generics/manufacturing-plants/ 2020-09-11T03:43:07+00:00 0.64 https://www.biocon.com/businesses/generics/api-rnd/ 2020-09-11T03:43:08+00:00 0.64 https://www.biocon.com/businesses/generics/formulation-rnd/ 2020-09-11T03:43:10+00:00 0.64 https://www.biocon.com/businesses/biosimilars/understanding-biologics/ 2020-09-11T03:43:11+00:00 0.64 https://www.biocon.com/businesses/biosimilars/understanding-biosimilars/ 2020-09-11T03:43:12+00:00 0.64 https://www.biocon.com/businesses/novel-biologics/itolizumab/ 2020-09-11T03:43:16+00:00 0.64 https://www.biocon.com/businesses/novel-biologics/insulin-tregopil/ 2020-09-11T03:43:17+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/07/CEO_Message.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/investor-relations/financial-information/annual-reports/annual-reports-archive/ 2020-09-11T03:43:22+00:00 0.64 https://www.biocon.com/docs/OutcomeOfBM_Biocon_20200723.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/investor-relations/financial-information/quarterly-reports/fy-2019-20/ 2020-09-11T03:43:23+00:00 0.64 https://www.biocon.com/docs/Biocon-Q1-FY21-Earnings-Call-Transcript.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/07/Biocon-_Audit-Committee-_2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/07/Biocon_-Nomination-Remuneration-Committee_2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/07/Biocon-RMC_Charter-2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/07/Biocon_CSR_Policy_2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/07/Biocon_Stakeholders-Relationship-Committee_2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/IEPF_FAQs.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/BM_Intimation_Biocon_July2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/BM_Intimation_Biocon_April2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200907.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200904.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeetin-20200903.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200820.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200814.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200812.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20200810.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200805.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200804.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200630.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20200626.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200625.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200618.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200615.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20200612.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200611.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200610.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/IR_PPT-20206008.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200605.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200603.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200602.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200601.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200529.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20200527.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-20200521.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20200520.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20200420.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200402.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200313.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200309.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20200306.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200226.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200220.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200218.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200212.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/IR_Presentation_10022020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20200130.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191212.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191211.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191210.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191206.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191205.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191204.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191128.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191121.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting20191112.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_20191105.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_Oct31.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_oct1.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-27-09-2019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_IR_meeting_Sept_24.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_Sep19.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/BioconPressRelease_12SEP19.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/IRPPT_Sep_11.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_Sep_11.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_Sep_10.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/IRPPT.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/sep06InvestorMeeting.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/sep-04InvestorMeeting.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_29_August_2019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_August2019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-210819.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_Aug03.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Investor_meeting.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_July_30.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_280619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_270619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_190619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_170619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting140619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/IR_PPT_130619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting120619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting070619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_0400619.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_May31_2019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_Intimation.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/IR_Presentation_Disclosure.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_May16.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting_090519.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-070519.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-030519.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/InvestorMeeting-30-04-19.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_BBIL_20200831.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Impact_of_Covid19_Biocon_SEs_Intimation.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/BBIL_SHA_SSA_Signed_Biocon.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_31072020_BBIL_TATA.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_Q1FY21.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_20200721.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_20200711.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_Statement_Biocon_20200227.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon%20and%20Mylan%20Announce%20U.S.%20FDA%20Approval%20of%20Semglee%E2%84%A2-insulin%20glargine%20injection.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_PR_20200605.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_01062020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_27052020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_PressRelease_19052020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_BioconLimited_14052020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_Biocon_12052020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_08052020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_28042020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_16042020_Biocon.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/PressRelease_Biocon_20200414.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_20200401_Biocon.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/SHP%20for%20Website2020-2021.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/SHP%20for%20Website_Q1.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/SHP%20for%20Website_H1.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/SHP%20for%20Website_Dec2019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Shareholding%20Patter_March%2031,%202020_Biocon.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Corporate_Governance_Report_Website-2020-2021.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Corporate_Governance_Report_Website.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Corporate_Governance_Report_Sept%202019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Corporate_Governance_Report_Website_Dec2019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Corporate_Governance_Report_FY_20200504.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_VC_AGM_Post_02072020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Intimation_IEPF_20200623.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_RPT_Disclosure-20200611.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/BBIL_Allotment_TATA-CAPITAL_03092020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_IntimationtoSEs_MOA_21082020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/VotingResults_AGM_Biocon_SE_july2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_AGM_Proceedings_July2020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_AGM%20Intimation_SEs_02072020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Outocome_of_BoardMeeting_Biocon_14052020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Appointment_Biocon_CFO_14052020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/OutcomeOfBM_Biocon_Jan23012020.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/whistle-blower-integrity-policy/ 2020-09-11T03:43:35+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-named-ey-entrepreneur-of-the-year-india-2019/ 2020-09-11T03:43:37+00:00 0.64 https://www.biocon.com/careers/functions/research-and-development/ 2020-09-11T03:43:38+00:00 0.64 https://www.biocon.com/careers/functions/manufacturing/ 2020-09-11T03:43:39+00:00 0.64 https://www.biocon.com/careers/functions/quality-and-regulatory/ 2020-09-11T03:43:41+00:00 0.64 https://www.biocon.com/careers/functions/business-development/ 2020-09-11T03:43:42+00:00 0.64 https://www.biocon.com/careers/functions/sales-and-marketing/ 2020-09-11T03:43:43+00:00 0.64 https://www.biocon.com/careers/functions/medical-sales-representatives/ 2020-09-11T03:43:45+00:00 0.64 https://www.biocon.com/careers/functions/enabling-functions/ 2020-09-11T03:43:46+00:00 0.64 https://www.biocon.com/careers/learning-development/digital-learning-3/ 2020-09-11T03:43:47+00:00 0.64 https://www.biocon.com/careers/learning-development/audit-readiness-programs-2/ 2020-09-11T03:43:49+00:00 0.64 https://www.biocon.com/careers/learning-development/leadership-programs-2/ 2020-09-11T03:43:50+00:00 0.64 https://www.biocon.com/careers/learning-development/technical-programs-2/ 2020-09-11T03:43:51+00:00 0.64 https://www.biocon.com/careers/learning-development/certifications-3/ 2020-09-11T03:43:53+00:00 0.64 https://www.biocon.com/careers/learning-development/sponsoring-higher-education-2/ 2020-09-11T03:43:54+00:00 0.64 https://www.biocon.com/careers/learning-development/behavioural-skills-training/ 2020-09-11T03:43:55+00:00 0.64 https://www.biocon.com/docs/Biocon_CSR_Policy_2018_24-01-2019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/responsibility/sustainability/safer-workplace/ 2020-09-11T03:43:57+00:00 0.64 https://www.biocon.com/responsibility/sustainability/an-environment-of-change/ 2020-09-11T03:43:58+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/ 2020-09-11T03:43:59+00:00 0.64 https://www.biocon.com/news-biocon/corporate-press-kit/ 2020-09-11T03:44:01+00:00 0.64 https://www.biocon.com/biocon-biologics-and-voluntis-join-hands-for-global-collaboration-on-digital-therapeutics-for-insulins/ 2020-09-11T03:44:02+00:00 0.64 https://www.biocon.com/biocon-presented-insights-into-clinical-study-that-enabled-dcgi-approval-of-itolizumab-for-covid19/ 2020-09-11T03:44:04+00:00 0.64 https://www.biocon.com/biocons-breakthrough-drug-itolizumab-receives-dcgi-nod-for-emergency-use-in-moderate-to-severe-covid-19-patients/ 2020-09-11T03:44:05+00:00 0.64 https://www.biocon.com/biocon-pharma-and-dksh-collaborate-to-commercialize-seven-generic-formulations-in-south-east-asia-markets/ 2020-09-11T03:44:06+00:00 0.64 https://www.biocon.com/biocon-and-mylan-announce-u-s-fda-approval-of-semglee-insulin-glargine-injection/ 2020-09-11T03:44:08+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-wins-ey-world-entrepreneur-of-the-year-2020-award/ 2020-09-11T03:44:09+00:00 0.64 https://www.biocon.com/biocons-partner-mylan-receives-favourable-ruling-from-u-s-ptab-on-sanofis-four-device-patents-for-lantus-solostar/ 2020-09-11T03:44:11+00:00 0.64 https://www.biocon.com/biocon-biologics-receives-dcgi-approval-for-emergency-use-of-cytosorb-to-treat-critical-covid-19-patients/ 2020-09-11T03:44:12+00:00 0.64 https://www.biocon.com/biocon-biologics-receives-eu-gmp-certification-for-multiple-biosimilars-manufacturing-facilities-in-bengaluru-expands-its-manufacturing-capacity/ 2020-09-11T03:44:13+00:00 0.64 https://www.biocon.com/biocon-earnings-q4fy20-revenue-up-6-at-rs-1644-cr-ebitda-down-11-at-rs-382-cr-net-profit-down-42-at-rs-123-cr/ 2020-09-11T03:44:15+00:00 0.64 https://www.biocon.com/biocon-and-mylan-launch-fulphila-biosimilar-pegfilgrastim-in-canada/ 2020-09-11T03:44:16+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-recognized-among-worlds-top-20-inspirational-leaders-in-biopharmaceuticals-in-the-medicine-maker-power-list-2020/ 2020-09-11T03:44:17+00:00 0.64 https://www.biocon.com/biocon-and-mylan-launch-fulphila-biosimilar-pegfilgrastim-in-australia/ 2020-09-11T03:44:19+00:00 0.64 https://www.biocon.com/biocon-biocon-biologics-ensuring-manufacturing-of-life-saving-medicines-for-patients-partners-and-customers/ 2020-09-11T03:44:20+00:00 0.64 https://www.biocon.com/biocon-mylan-win-patent-litigation-asserted-by-sanofi-for-insulin-glargine-device-patent-in-u-s/ 2020-09-11T03:44:21+00:00 0.64 https://www.biocon.com/u-s-fda-accepts-biologics-license-application-bla-for-mylan-and-biocons-proposed-biosimilar-bevacizumab-for-review/ 2020-09-11T03:44:23+00:00 0.64 https://www.biocon.com/biocon-q3fy20-earnings-revenue-at-rs-1784-cr-up-14-ebitda-at-rs-480-cr-up-18-net-profit-before-exceptional-item-at-rs-225-cr-up-6/ 2020-09-11T03:44:24+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-honoured-with-order-of-australia-australias-highest-civilian-honour/ 2020-09-11T03:44:26+00:00 0.64 https://www.biocon.com/true-north-to-invest-rs-536-25-crore-in-biocon-biologics-for-2-44-stake/ 2020-09-11T03:44:27+00:00 0.64 https://www.biocon.com/biocon-biologics-appoints-m-b-chinappa-as-chief-financial-officer/ 2020-09-11T03:44:28+00:00 0.64 https://www.biocon.com/biocon-equillium-expand-exclusive-licensing-agreement-for-itolizumab-to-include-australia-and-new-zealand/ 2020-09-11T03:44:30+00:00 0.64 https://www.biocon.com/biocon-biologics-symposium-on-100-years-of-insulin-delivering-on-universal-access-equitable-care-resonates-well-with-leading-kols-at-idf-congress-2019/ 2020-09-11T03:44:31+00:00 0.64 https://www.biocon.com/biocon-biologics-takes-forward-its-mission-to-unlock-universal-access-to-insulins-globally/ 2020-09-11T03:44:32+00:00 0.64 https://www.biocon.com/siddharth-mittal-takes-over-as-ceo-and-joint-managing-director-of-biocon-limited/ 2020-09-11T03:44:34+00:00 0.64 https://www.biocon.com/biocon-and-mylan-launch-trastuzumab-biosimilar-ogivri-trastuzumab-dkst-in-the-u-s/ 2020-09-11T03:44:35+00:00 0.64 https://www.biocon.com/usfda-approves-biocons-sbla-for-pegfilgrastim-new-manufacturing-facility/ 2020-09-11T03:44:36+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-conferred-with-lifetime-achievement-award-by-indian-council-of-medical-research/ 2020-09-11T03:44:38+00:00 0.64 https://www.biocon.com/biocon-features-in-the-prestigious-asia-ip-elite-list-for-the-fourth-consecutive-year/ 2020-09-11T03:44:39+00:00 0.64 https://www.biocon.com/biocons-biologics-drug-products-facility-in-bengaluru-receives-eir-from-u-s-fda/ 2020-09-11T03:44:40+00:00 0.64 https://www.biocon.com/biocon-moves-up-to-rank-no-6-on-science-careers-top-20-global-pharma-biotech-employers-list-2019/ 2020-09-11T03:44:42+00:00 0.64 https://www.biocon.com/biocon-q2fy20-earnings-revenue-at-rs-1611-cr-up-17-ebitda-at-rs-441-cr-up-12-net-profit-excluding-exceptional-item-at-rs-189-cr-up-3/ 2020-09-11T03:44:43+00:00 0.64 https://www.biocon.com/biocon-biologics-just-evotec-biologics-sign-licensing-deal-for-a-biosimilar-asset/ 2020-09-11T03:44:44+00:00 0.64 https://www.biocon.com/biocon-and-mylan-launch-first-insulin-glargine-biosimilar-semglee-in-australia/ 2020-09-11T03:44:46+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-promises-to-enable-universal-access-to-rh-insulin-by-reducing-prices-to-less-than-10-us-cents-day-for-lmics/ 2020-09-11T03:44:47+00:00 0.64 https://www.biocon.com/biocon-biologics-expands-its-rd-footprint-through-acquisition/ 2020-09-11T03:44:49+00:00 0.64 https://www.biocon.com/biocon-licenses-three-generic-formulation-products-to-china-medical-system-holdings/ 2020-09-11T03:44:50+00:00 0.64 https://www.biocon.com/biocons-malaysia-insulin-glargine-manufacturing-facility-receives-eu-gmp-certification-provides-fillip-to-its-capacity/ 2020-09-11T03:44:51+00:00 0.64 https://www.biocon.com/mylan-and-biocon-launch-first-trastuzumab-biosimilar-ogivri-in-australia/ 2020-09-11T03:44:53+00:00 0.64 https://www.biocon.com/biocon-q1fy20-revenue-rs-1490-cr-up-25-ebitda-up-51-at-rs-462-cr-net-profit-excluding-exceptional-item-up-86-at-rs-223-cr/ 2020-09-11T03:44:54+00:00 0.64 https://www.biocon.com/biocon-biologics-facilities-in-bengaluru-receive-eu-gmp-certification/ 2020-09-11T03:44:55+00:00 0.64 https://www.biocon.com/health-canada-approves-biocon-and-mylans-ogivri-the-first-trastuzumab-biosimilar-for-the-treatment-of-her2-positive-breast-and-gastric-cancers/ 2020-09-11T03:44:57+00:00 0.64 https://www.biocon.com/biocon-and-mylan-to-present-final-overall-survival-data-for-ogivritmtrastuzumab-dkst-a-biosimilar-to-herceptin-at-the-american-society-of-clinical-oncology-asco-annual-meeting-2/ 2020-09-11T03:44:58+00:00 0.64 https://www.biocon.com/biocon-q4fy19-revenue-rs-1557-cr-up-26-ebitda-up-43-at-rs-431-cr-net-profit-up-64-at-rs-214-cr-fy19-revenue-up-31-at-rs-5659-cr-net-profit-up-143-at-rs-905-cr/ 2020-09-11T03:45:00+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-conferred-with-honorary-doctorate-from-deakin-university-australia/ 2020-09-11T03:45:01+00:00 0.64 https://www.biocon.com/biocon-appoints-dr-christiane-hamacher-as-ceo-of-biocon-biologics-india-limited/ 2020-09-11T03:45:02+00:00 0.64 https://www.biocon.com/kiran-mazumdar-shaw-elected-as-member-of-the-national-academy-of-engineering-u-s/ 2020-09-11T03:45:04+00:00 0.64 https://www.biocon.com/biocon-q3fy19-earnings-revenue-at-rs-1566-cr-up-43-net-profit-at-rs-217-cr-up-136-ebitda-at-rs-406-cr-up-59/ 2020-09-11T03:45:05+00:00 0.64 https://www.biocon.com/biocon-biologics-drug-substance-facilities-in-bengaluru-receive-eu-gmp-certification/ 2020-09-11T03:45:06+00:00 0.64 https://www.biocon.com/biocon-receives-eir-for-small-molecules-api-manufacturing-facility-for-pre-approval-and-gmp-u-s-fda-inspection/ 2020-09-11T03:45:08+00:00 0.64 https://www.biocon.com/biocon-biologics-receives-eir-from-u-s-fda-for-two-manufacturing-facilities-inspection-stands-closed/ 2020-09-11T03:45:09+00:00 0.64 https://www.biocon.com/biocons-insulin-manufacturing-facility-in-malaysia-receives-eir-from-u-s-fda-with-voluntary-action-indicated-vai-classification-inspection-stands-closed/ 2020-09-11T03:45:10+00:00 0.64 https://www.biocon.com/biocon-receives-eir-for-small-molecules-api-manufacturing-facility-for-post-approval-and-gmp-u-s-fda-inspection/ 2020-09-11T03:45:12+00:00 0.64 https://www.biocon.com/biocons-small-molecules-api-manufacturing-facility-completes-post-approval-and-gmp-u-s-fda-inspection/ 2020-09-11T03:45:13+00:00 0.64 https://www.biocon.com/biocons-insulin-manufacturing-facility-in-malaysia-completes-u-s-fda-pai-inspection/ 2020-09-11T03:45:15+00:00 0.64 https://www.biocon.com/biocons-small-molecules-api-manufacturing-facility-completes-pre-approval-and-gmp-u-s-fda-inspection/ 2020-09-11T03:45:16+00:00 0.64 https://www.biocon.com/biocons-oral-solid-dosage-manufacturing-facility-completes-pre-approval-u-s-fda-lnspection-with-zero-observations/ 2020-09-11T03:45:17+00:00 0.64 https://www.biocon.com/docs/Biocon-Company-Statement-20190920.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/31082019CompanyStatement.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/08072019CompanyStatement.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/CompanyStatement06032019.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/companystatement19dec2018.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/pressrelease_210218.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/BioconStatement_FDAfee_Dec13.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_Statement_Biocon's%20Facility%20Receives%20EIR%20with%20VAI%20status,%20Inspection%20Closed_20Nov.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Biocon_Statement_Biocon's%20Facility%20Receives%20EIR%20with%20VAI%20status,%20Inspection%20Closed_20Nov.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Press%20Release_Nov%207.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/Company_Statement_Health_Canada_061017.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/10052017_biocon_statement_usfda_483s_pr.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/28th-November-2019_BusinessStandard__Ahmedabad.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/28th-November-2019_TheFinancialExpress__Bangalore.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/30th-October-2019_TheHindu__Bangalore.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/26th-October-2019_BusinessStandard__Bangalore.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/28th-September-2019_TheHindu__Bangalore.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/27th-September-2019_TOI__Bangalore.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/25th-October-2019_Mint__Bangalore.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/25th-September-2019_TOI__Chennai.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/docs/25th_September_2019_TOI_Bengaluru.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/biocon-campus/ 2020-09-11T03:45:24+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/kiran-mazumdar-shaw/ 2020-09-11T03:45:26+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/leadership-team/ 2020-09-11T03:45:29+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/manufacturing-locations/ 2020-09-11T03:45:37+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/research-centre/ 2020-09-11T03:45:40+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/company-logos-2/ 2020-09-11T03:45:42+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/biocon-foundation/ 2020-09-11T03:45:50+00:00 0.64 https://www.biocon.com/news-biocon/image-gallery-biocon/biocon-academy/ 2020-09-11T03:45:53+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/biocon-corporate-video/ 2020-09-11T03:45:55+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/kiran-mazumdar-shaw/ 2020-09-11T03:45:56+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/stories-of-hope/ 2020-09-11T03:45:57+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/hebbagodi-lake-revival/ 2020-09-11T03:45:59+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/events/ 2020-09-11T03:46:00+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/mission/ 2020-09-11T03:46:01+00:00 0.64 https://www.biocon.com/news-biocon/video-gallery-biocon/proud-moments/ 2020-09-11T03:46:03+00:00 0.64 https://www.biocon.com/more/contact-us/overseas-offices/ 2020-09-11T03:46:04+00:00 0.64 https://www.biocon.com/more/patient-literature/lung-cancer/ 2020-09-11T03:46:05+00:00 0.64 https://www.biocon.com/more/patient-literature/renal-cancer/ 2020-09-11T03:46:07+00:00 0.64 https://www.biocon.com/more/patient-literature/head-and-neck-cancer/ 2020-09-11T03:46:09+00:00 0.64 https://www.biocon.com/more/patient-literature/ovarian-cancer/ 2020-09-11T03:46:10+00:00 0.64 https://www.biocon.com/more/patient-literature/cervical-cancer/ 2020-09-11T03:46:11+00:00 0.64 https://www.biocon.com/more/patient-literature/breast-cancer/ 2020-09-11T03:46:13+00:00 0.64 https://www.biocon.com/more/patient-literature/colorectal-cancer/ 2020-09-11T03:46:14+00:00 0.64 https://www.biocon.com/more/patient-literature/psoriasis/ 2020-09-11T03:46:15+00:00 0.64 https://www.biocon.com/more/patient-literature/sepsis/ 2020-09-11T03:46:17+00:00 0.64 https://www.biocon.com/more/patient-literature/diabetes/ 2020-09-11T03:46:18+00:00 0.64 https://www.biocon.com/business-continuity-statement/ 2020-09-11T03:46:21+00:00 0.64 https://www.biocon.com/docs/Biocon%20Biologics_Mylan_PR_Semglee_US_Aug-31.pdf 2020-09-11T03:46:26+00:00 0.64 https://www.biocon.com/wp-content/uploads/2020/08/Kiran-Mazumdar-Shaw_Profile_20200721.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/wp-content/uploads/2020/08/Siddharth-Mittal-profile-20200402.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/wp-content/uploads/2020/08/ChristianeHamacher_2019.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/wp-content/uploads/2020/08/Jonathan-profile.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/ACTIBLOK%20IPR%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BASALOG%203%20ML,%205%20ML%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BASALOG%20ONE%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BASALOG%20100IU%20REFIL%20LEAFLET.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BESTOR%205-10-20%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BLISTO%201-2-4%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BLISTO%201%202%20MF%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BLISTO%204%20MF%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/BLISTO%20TRIO%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%2050-50%20100%20IU%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%2030-70%20100%20IU%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%20N%20100%20IU%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%20R%20100%20IU%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%2030-70%2040%20IU%20%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%2050-50%2040%20IU%20%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%20N%2040%20IU%20%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%20R%2040%20IU%20%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUPen%20Pro%20IFU.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%20-N-%20REFILL%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%20-R-%20REFILL%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN-50%2050%20REFILL%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/INSUGEN%20-30-70-%20REFILL%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/METADOZE%20IPR%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/ZUKER-MF%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/TELMISAT%20%E2%80%93%20H,%20%2080%20H.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/TELMISAT%20CT%2040%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/TELMISAT%20AM%205.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/Telmisat%20PI%2020%2040%2080.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/STATIX%20F%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/metabolics/STATIX%2010-20-40%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/onco/CANMAB%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/onco/BIOMAB%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/onco/KRABEVA%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/onco/ABSTET%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/onco/FOSAPORT%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/onco/ERYPRO%20SAFE%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/PSORID-CAPSULES%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/PSORID%20Oral%20%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/TBIS%200.1%20OINTMNET%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/TBIS%20LOTION-PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/PICON%20OINTMENT%20PI%20new.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/PICON%20LOTION%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/ALIZAP%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/ARETHA%20-%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/PSIEN%20500%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/CALPSOR%2030%20g%20OINTMENT%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/CALPSOR%20LOTION%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/CALPSOR%20C%20%2030%20g%20OINTMENT%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/CALPSOR%20C%20Lotion%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/immuno/ALZUMAB%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/nephro/TACROGRAF%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/nephro/ADVACAN%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/nephro/RENODAPT%20250.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/nephro/RENODAPT%20500%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/nephro/RENODAPT%20750%20PI.pdf 2020-09-11T03:46:26+00:00 0.51 https://www.biocon.com/docs/domestic-market-pi/nephro/ERYPRO%20PI%20vial.pdf 2020-09-11T03:46:26+00:00 0.51